Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer.
Tsimberidou AM, Alayli FA, Okrah K, Drakaki A, Khalil DN, Kummar S, Khan SA, Hodi FS, Oh DY, Cabanski CR, Gautam S, Meier SL, Amouzgar M, Pfeiffer SM, Kageyama R, Yang E, Spasic M, Tetzlaff MT, Foo WC, Hollmann TJ, Li Y, Adamow M, Wong P, Moore JS, Velichko S, Chen RO, Kumar D, Bucktrout S, Ibrahim R, Dugan U, Salvador L, Hubbard-Lucey VM, O'Donnell-Tormey J, Santulli-Marotto S, Butterfield LH, Da Silva DM, Fairchild J, LaVallee TM, Padrón LJ, Sharma P.
Tsimberidou AM, et al. Among authors: kageyama r.
J Exp Med. 2024 Oct 7;221(10):e20240152. doi: 10.1084/jem.20240152. Epub 2024 Aug 27.
J Exp Med. 2024.
PMID: 39190534
Free PMC article.